Who
Dawn Carter Bir
Director
Company insider
Files Form 4 as: Interim President and CEO, Geron; Director, Soleno Therapeutics; Director, Filana Therapeutics; Chief Commercial Officer, Reata Pharmaceuticals.
In numbers
- Trades disclosed
- 66
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $26.1M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 7 Dec 2016
- Last trade
- 20 May 2026
- Last filed
- 26 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 May 2026filed 26 May 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 20 May 2026filed 26 May 2026 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —220,000 at $0.00 | filing |
| 18 May 2026filed 18 May 2026 | Soleno TherapeuticsBiotechnology | SEC FORM 4 Code D | —16,991 | filing |
| 18 May 2026filed 18 May 2026 | Soleno Therapeutics | SEC FORM 4 Code D | —16,991 | filing |
| 21 Oct 2025filed 22 Oct 2025 | FLNA Filana Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | Soleno Therapeutics | SEC FORM 4 Code A | —3,991 at $0.00 | filing |
| 21 May 2025filed 22 May 2025 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 15 Aug 2024filed 16 Aug 2024 | Soleno Therapeutics | SEC FORM 4 Code A | —13,000 at $0.00 | filing |
| 9 May 2024filed 10 May 2024 | GERN Geronoption or derivative · Biotechnology | SEC FORM 4 Code A | —180,000 at $0.00 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —16,500 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —70,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —63,650 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —71,300 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —34,500 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —17,250 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —17,250 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —24,000 | filing |
| 26 Sep 2023filed 26 Sep 2023 | Reata Pharmaceuticals | SEC FORM 4 Code D | —33,805 | filing |
| 16 Aug 2023filed 17 Aug 2023 | Reata Pharmaceuticals | SEC FORM 4 Sold | $67K398 at $168.33 | filing |
| 15 Aug 2023filed 17 Aug 2023 | Reata Pharmaceuticals | SEC FORM 4 Sold | $136K807 at $169.04 | filing |
News
No headline names them, or the companies they trade most, lately.